Telangana Next-Gen Life Sciences Policy 2026–2030

Foreword

Sri A Revanth Reddy, The Hon’ble Chief Minister of Telangana

Telangana has firmly established itself as a global leader in the life sciences sector. With over 2000 companies operating in various life sciences streams and an installed manufacturing capacity accounting for 1/3rd of the Global Vaccine production, Telangana is a powerhouse in the life sciences sector. The state’s robust infrastructure, my government’s progressive policies, and unparalleled talent pool have attracted investments and catalyzed groundbreaking advancements in pharmaceuticals, biotechnology, medical technologies, and healthcare.

This Life Sciences Policy 2026-2030 reflects our unwavering commitment to excellence and sustainable growth. By consolidating our strengths and venturing into transformative domains such as biologics, precision medicine, and biomanufacturing, we are poised to shape Telangana into one of the top life sciences clusters in the world.

Through this policy, I reaffirm our vision of not just fostering industrial growth but also enhancing healthcare accessibility for all, contributing to global health and well-being. Together, we will continue to chart an ambitious and inclusive path toward a healthier, more prosperous future.

Sri Duddilla Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications; Industries & Commerce and Legislative Affairs

Telangana’s life sciences sector is a key pillar of our state’s economic and innovation-driven growth. What is prideworthy is the fact that with 250+ FDA approved sites in Telangana, we are the largest concentration of FDA approved sites in the world. In Fiscal Year 2023-24, Telangana’s life sciences sector accounted for about 32% of the state’s total merchandise exports, contributing nearly INR 36,893 crore (USD 4.43 billion) out of INR 1.2 lakh crore (USD 14.4 billion) in overall exports.

With pioneering initiatives like Genome Valley, the Medical Devices Park, and a robust pharmaceutical manufacturing ecosystem, Telangana has become synonymous with forward-thinking strategies and transformative development.

The Life Sciences Policy 2026-2030 builds on our legacy, embracing cutting-edge technologies, fostering global collaborations, and enabling advanced manufacturing. It underscores our commitment to nurturing talent, driving digital transformation, and creating a dynamic ecosystem that continues to attract global enterprises.

This policy reflects Telangana’s vision of being at the forefront of global healthcare innovation. I warmly invite stakeholders across industries, academia, and research to join us in shaping the future.

Sri Sanjay Kumar, IAS, Special Chief Secretary for Information Technology, Electronics & Communications; Industries & Commerce

In Telangana, the life sciences sector is not just an industry; it is a catalyst for global change. Over the past two decades, the state has built an unparalleled ecosystem that spans the entire value chain of healthcare and life sciences. From Genome Valley, India’s first and largest life sciences cluster, to our thriving medical devices ecosystem, and from world-class pharmaceutical manufacturing facilities to pioneering research and development centres, Telangana has emerged as a place where bold ideas are transformed into tangible solutions for humanity.

Our Life Sciences Policy 2026-2030 builds on this strong foundation and spirit of innovation. It is designed to accelerate the adoption of breakthrough technologies such as AI, digital health, and next-generation therapeutics, while nurturing skilled talent and fostering deep collaborations with global leaders. This policy is not merely a framework; it is a forward-looking vision to position Telangana at the very heart of worldwide healthcare innovation, discovery, and delivery.

As we look to the future, we invite changemakers, innovators, investors, and partners from across the globe to join us in this journey: to co-create solutions, drive impactful innovation, and shape a healthier, more equitable world together.

1Introduction

1.1National Scenario

India’s life sciences ecosystem is one of the largest and fastest-growing in the world, spanning pharmaceuticals, biotechnology, medical devices, and research services. The country is the third-largest producer of pharmaceuticals by volume, supplying about 20% of global generics and 60% of vaccines worldwide. Its bioeconomy grew to USD 165 billion in 2024, driven by rapid growth in biopharma, bio-industrial applications, and over 10,000 biotech startups, with projections to reach 35,000 by 2030. The medical devices sector, currently valued at around USD 18 billion, is expected to scale to USD 50 billion by 2030.

This growth is underpinned by a robust talent base, competitive manufacturing costs, and proactive policy support. Initiatives like the Production Linked Incentive (PLI) scheme, Research Linked Incentive (RLI) scheme, Anusandhan National Research Foundation 2023, the BioE3 Policy etc., are some of the measures that are actively encouraging the growth of the industry.

Telangana, a state nestled in the heart of India, has earned its reputation as an economic powerhouse and a dynamic hub for industrial growth. Boasting a robust industrial climate, Telangana stands at the forefront of progressive policies and visionary initiatives, making it a preferred destination for investors and businesses alike. Renowned for its strategic location, well-developed infrastructure, and a proactive government, the state has consistently fostered an environment conducive to innovation and industrial excellence. Telangana’s commitment to driving economic development is evident in its diverse industrial landscape, spanning sectors such as life sciences, information technology, and manufacturing, among others. With a legacy of success and a forward-thinking approach, Telangana continues to chart a trajectory of unparalleled growth, making it an ideal setting for the transformative initiatives outlined in this new Life Sciences Policy. This policy sets the stage for a state that not only cherishes its past achievements but is also resolutely focused on shaping a dynamic and thriving future in the realm of life sciences.

The life sciences sector in Telangana is broadly classified into the following sectors: Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics.

1.2Thriving Life Sciences Ecosystem

Telangana has a deep and enduring legacy in the life sciences sector, with Hyderabad emerging as a national and global hub over the past six decades. The genesis of the sector started with the establishment of Indian Drugs and Pharmaceuticals Limited in 1961. The city’s prominence worldwide began with the growth of pharmaceutical manufacturing in the 1980s and 1990s, when homegrown enterprises such as Dr. Reddy’s Laboratories, Divi’s Laboratories, Aurobindo Pharma, and Natco Pharma among others established operations and expanded rapidly into global markets.

Over time, Hyderabad also developed unparalleled expertise in vaccine research, development, and large-scale manufacturing. The early establishment of Genome Valley as India’s first life sciences R&D cluster further reinforced Telangana’s leadership position.

The life sciences sector in Telangana has become synonymous with innovation excellence, and cutting-edge advancements. Renowned as the life sciences capital of India, Telangana stands as a beacon of success in the global life sciences landscape.

Accounting for about one-third of global vaccine production and 40% to India’s pharma production, Telangana is home to over 2,000 life sciences companies, ranging from pharmaceutical giants to cutting-edge biotech firms.

2Key Highlights

01Manufacturing Excellence

Contributing 40% of India’s pharmaceutical production, Telangana stands as a global leader in manufacturing. In a unique distinction, the state is the only region in the world housing over 250 USFDA-approved manufacturing sites. The state has also earned the reputation of being the vaccine capital of the world and played a key role in saving millions of lives during the COVID-19 pandemic. With a total vaccine production capacity of approximately 14 billion doses, it has solidified its leadership position as a global vaccine hub. The state is also emerging as a leader in the manufacturing of medical devices and diagnostic equipment/reagents with a flourishing ecosystem.

02Pioneering Research and Development

Home to Asia’s epicentre for drug discovery and development, Hyderabad, Telangana fosters a culture of cutting-edge research and development. With over 5 million square feet of multi-tenanted laboratory facilities in Genome Valley, the region attracts top talent and drives breakthrough discoveries.

03Global Value Centres (GVCs) & Global Innovation Centres (GICs)

Hyderabad has emerged as the preferred location for life sciences, focused on Global Value Centres & Global Innovation Centres. Telangana boasts a vibrant ecosystem of digital GICs from global life sciences and healthcare players like Novartis, Amgen, Eli Lilly, MSD, Johnson & Johnson, Sanofi, Bristol Myers Squibb, Roche, Bayer, Medtronic, ThermoFisher, Optum, Legato Anthem, Providence, Evernorth, HCA Healthcare, Sandoz, IQVIA, among others focused on cutting-edge work in key R&D, analytics, innovation and engineering, contributing to a thriving ecosystem.

3Telangana Life Sciences Vision

In its unwavering pursuit of excellence and comprehensive progress, the vision for Telangana’s Life Sciences Policy aims to chart a dynamic course, positioning the state as an unparalleled global hub for life sciences.

We are committed to catalyzing robust socio-economic growth through strategic investments, job creation, and the nurturing of an innovation-centric environment. We aspire to cultivate an ecosystem that not only generates employment opportunities but also serves as a global catalyst for pioneering therapies, ensuring accessibility for our citizens and beyond.

01Become an Important Node in the Global Value Chain

Our vision focuses on creating an environment that attracts substantial investments, unlocking the potential for economic prosperity. By fostering a business-friendly ecosystem, we aim to stimulate industrial growth, promote entrepreneurship, and generate meaningful employment opportunities. Telangana aspires to become an important node in the global value chain for the life sciences sector, contributing to India’s economic landscape and setting new benchmarks in the field.

02Global Leadership in Healthcare

Telangana envisions a leadership role on the global stage in shaping the future of healthcare. Through cutting-edge research, strategic partnerships, and technological convergence, the state aims to drive transformative advancements in therapies and healthcare solutions. Acknowledging the transformative potential of technology in healthcare, the policy underscores the convergence of healthcare and technology. Investments in AI and other emerging technologies will revolutionize disease diagnosis and healthcare delivery, aligning with global industry trends.

03Catalyzing Innovation

Our goal is to cultivate an environment where innovation not only thrives but also drives transformative progress. By fostering strategic partnerships, building state-of-the-art infrastructure, offering research and development incentives, and establishing a supportive regulatory framework, we envision Telangana as a dynamic hub for cutting-edge discoveries and advancements that will redefine the boundaries of life sciences.

04Employment Generation

Our vision extends to creating a vibrant and resilient job market within the life sciences sector. Through targeted initiatives and collaborations, we aim to generate employment opportunities that empower individuals and nurture a skilled workforce equipped to navigate the challenges and seize the opportunities of the future.

05Access to Innovative Therapies

At the heart of our vision lies the principle that groundbreaking healthcare must be accessible to all. We are committed to breaking down barriers and ensuring that the benefits of innovative therapies reach every citizen of Telangana and beyond. By implementing progressive policies and enabling a robust clinical research framework, we aim to create a healthcare ecosystem that is inclusive, streamlined, and brings science directly to patients.

4Telangana Life Sciences Mission

• —Building a world-class life sciences ecosystem
• —Generate 500,000 new jobs & attract USD 25 billion investment
• —Giving a fillip to pure-play innovation
• —Create a robust ancillary ecosystem

5Current Endeavours and Future Roadmap

As Telangana embarks on a transformative journey, it unveils this visionary Life Sciences Policy, guided by a two-pronged approach:

01 — Consolidating Current Strengths

Telangana’s legacy in pharmaceutical and vaccine production stands as a cornerstone of its current strength. This new policy envisages sustaining and enhancing this prowess by providing a conducive environment for companies engaged in pharmaceutical and biotech R&D and manufacturing.

02 — Building New Capabilities and Capacities

Recognizing the dynamic nature of the life sciences sector, the policy places strategic emphasis on diversification and cultivation of new capabilities. Emerging growth areas such as biologics/biosimilars, peptides, oligonucleotides, antibody drug conjugates, cell and gene therapies, mRNA and CRISPR platforms, genomics, diagnostics, medical electronics, and digital health will be key focal points.

5.1Current Strengths

• 40%Of India’s pharmaceutical production
• 250+USFDA-approved manufacturing sites
• 2,000+Life Sciences companies
• 20+Life Sciences and MedTech incubators

5.2New Capabilities

Telangana’s new Life Sciences Policy is a holistic and forward-looking framework. It aims to strengthen the state’s position as a leader in life sciences and envisions Telangana as one of the world’s top 3 life sciences clusters by 2030. The policy sets the stage for a vibrant, innovative, and globally competitive life sciences ecosystem through a strategic blend of consolidating existing strengths and venturing into new frontiers. This marks a significant leap towards a future where Telangana continues to inspire breakthroughs and advancements across the field of life sciences.

These areas will serve as pivotal focal points as Telangana pioneers advancements in the life sciences field. The subsequent sections of this policy document will delve deeper into each of these objectives, outlining precise action points and strategies to guide the state towards a future defined by unparalleled achievements in the realm of life sciences.

5.3Ecosystem Enablers

Genome Valley

Genome Valley is India’s first organized cluster for life sciences R&D and clean manufacturing activities, with world-class infrastructure facilities. It is the most active cluster in the country with over 250 organizations and major vaccine manufacturers with WHO-Prequalified vaccines for global supply. Recently, the state will expand Genome Valley with another 300 acres of land, along with major infrastructure upgrades aimed at enhancing and expanding existing facilities to further augment its capabilities.

Medical Devices Park

It is one of India’s largest medical devices clusters spanning over 302 acres, provides a comprehensive range of facilities to support innovation, research, development, manufacturing, warehousing, and logistics. With approximately 60 companies establishing their R&D and manufacturing facilities within the park, it has created over 7,000 job opportunities. This Park hosts Asia’s largest stent manufacturing facility operated by SMT. Additionally, Medtronic has established one of its largest development centres in Hyderabad, recently announcing an investment of half a billion USD in the city and Olympus Corporation is also establishing a Research and Development Centre in Hyderabad.

Pharma Villages

As part of a strategy to decentralize the life sciences industry, the state is embarking on the establishment of 10 pharma villages. The establishment of pharma villages aligns with the goal of creating robust and distributed life sciences hubs, fostering collaboration, innovation, and economic growth, while ensuring a well-connected and resilient pharmaceutical industry.

1Bio

Telangana’s commitment to innovation is further evident in the establishment of the 1Bio, a first-of-its-kind Growth-Phase Centre and Biopharma Scale-up Manufacturing facility in India. This hub aims to propel advancements in the biologics & vaccine development, as well as Cell and Gene Therapies, and develop state-of-the-art, turnkey lab infrastructure for working on disruptive ideas.

WEF C4IR

The Government of Telangana and the World Economic Forum (WEF) collaborated to establish the 19th Centre of the WEF’s Fourth Industrial Revolution C4IR Network and the world’s first centre focused on healthcare and life sciences in Hyderabad. With its strong ecosystem and abundant talent pool, Hyderabad provides a thriving base for innovation. C4IR Telangana is driving initiatives such as a skilling program to develop a highly skilled and competent workforce to bridge the demand-supply gap in the industry. The Clinical Innovation Sandbox initiative aims to accelerate the validation process, expedite innovative studies, and serve as a benchmark for the world. The centre will play a crucial role in scaling networks, fostering innovation, attracting talent, and enhancing regulatory support through its core focus areas and industry collaboration.

Centre of Excellence on AMR

Telangana is establishing a unique, world-class Antimicrobial Centre of Excellence jointly funded by the Government of India and The Government of Telangana. This CoE will mark a significant milestone in the journey towards combating antimicrobial resistance effectively. The CoE will feature sophisticated facilities to train and equip MSME partners with the latest technologies, thereby increasing their global competitiveness.

Hyderabad Pharma and Infrastructure Technologies Ltd (HPITL)

Hyderabad Pharma Infrastructure and Technologies Ltd (HPITL) operates laboratories and a Human Resource Development (HRD) centre in Jeedimetla, catering to the needs of MSME units. These facilities have been identified for an upgradation to maximize the benefits to companies in Telangana.

BioAsia Convention

It is an annual flagship event co-hosted by the Government of Telangana, attracting over 3,000 global leaders from around the world each year. It serves as a forum for diverse networking activities, including business partnering, exhibitions, technology conferences featuring talks from global thought leaders, interactive sessions, CEO Conclave, startup showcases, and bio park visits. In its two-decade journey, BioAsia has facilitated over 20,000 B2B, B2R, and R2R meetings, engaging luminaries from more than 95 countries, resulting in over 250 Letters of Intent, bilateral cooperation agreements, and Memoranda of Understanding. The event has also generated more than 30 knowledge papers and policy recommendations, contributing significantly to trade and investment, surpassing USD 2.5 billion.

Flow Chemistry Hub

The Flow Chemistry Technology Hub (FCT Hub), initiated by the Telangana government, is a collaborative effort with stakeholders including Dr. Reddy’s Laboratories and Laurus Labs. Located in the premier Dr. Reddy’s Institute of Life Sciences (DRILS) in Hyderabad, it advances pharmaceutical R&D through flow chemistry and promotes continuous green synthesis for API manufacturing. Funded by industry partners and supported by government facilitation, the hub benefits from scientific mentorship by world-renowned scientists, including Prof. Govardhan Mehta (UoH), Prof. Steven Ley (University of Cambridge, UK), Prof. Oliver Kappe (University of Graz, Austria), Prof. Shu Kobayashi (University of Tokyo, Japan), among others.

Society for Biotechnology Incubation Centre (SBTIC)

Established in 2006 through a collaboration between the Department of Biotechnology (DBT), Government of India, Government of Telangana and Indian Institute of Chemical Technology (IICT). The Biotechnology Incubation Centre (BTIC) is an innovation hub spanning 35,000 square feet with a mix of plug-and-play modular lab spaces, best-in-class office spaces, and an Advanced Analytical Characterisation Resource laboratory. Purpose-built to foster the growth of early-stage startups and entrepreneurs in the pharma & life sciences sector. BTIC aims to catalyze breakthrough discoveries and expedite commercialization efforts. Currently, the facility incubates over 10 startups and SME companies. Furthermore, it houses a 200L cGMP biotechnology pilot plant for manufacturing and process development of microbial and cell culture applications.

Global Partnerships

Strategic collaborations with leading global institutions such as the region of Flanders (Belgium), the National Institute for Bioprocessing Research and Training (NIBRT, Ireland), Wallonia (Belgium), and K-NIBRT (South Korea) have positioned Telangana as a frontrunner in the field of biomanufacturing. This status as a global hub for cutting-edge biomanufacturing is further reinforced by strategic partnerships, including the WHO’s decision to establish an mRNA vaccine hub in Hyderabad and a landmark alliance with Health Innovation Manchester (UK). Moreover, Telangana’s collaboration with the University of Queensland (Australia) focuses on AI-driven healthcare research and digital innovation, while its partnership with the Biopôle Life Sciences Cluster (Switzerland) aims to foster innovation-led exchanges between Genome Valley and the Swiss biotech ecosystem.

5.4Strategic Focus Areas: Telangana is a frontrunner, yet relentless in its pursuit of progress

Telangana, at the forefront of life sciences innovation, has not just set the bar as a leader but has raised it to new heights. Yet, on our journey, we embrace the idea that progress is an endless adventure, and the State remains committed to navigating the dynamic landscape of the future. Telangana propels forward with an unwavering dedication and a pioneering spirit.

This steadfast commitment propels us into the next phase of our journey, where we unveil a strategic and visionary roadmap that promises to reshape the very essence of success and innovation. Within the folds of the new policy, we have identified multiple focal points to ignite our growth engine, ensuring a vibrant and thriving future.

01 — Frontier R&D and Advanced Manufacturing

In our quest for excellence and the transition from volume to value, the Life Sciences Policy places a strategic focus on Frontier R&D and advancing manufacturing capabilities within the state. By embracing state-of-the-art technologies, innovative processes, and a conducive regulatory framework, Telangana aims to catalyze the growth of advanced manufacturing in the life sciences sector in areas such as biomanufacturing, precision fermentation, peptides, oligonucleotides, antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs) and multispecific antibodies, cell and gene therapies, mRNA, and CRISPR platforms. These areas will be a primary focus for the government, which will periodically notify the list of additional activities covered under the advanced manufacturing theme. This initiative is designed to elevate our innovation prowess, positioning Telangana as a key player in the global landscape of the pharmaceutical and biotechnological sectors.

02 — Clinical Research

Recognizing the pivotal role of clinical trials in advancing biomedical research, the policy aims to strengthen Telangana’s clinical trial ecosystem. By streamlining processes, enhancing regulatory clarity, and encouraging collaborative initiatives, Telangana is poised to become a preferred destination for conducting clinical trials. These efforts will ensure that innovative therapies are accessible even to the farthest corners of the state, promoting better healthcare outcomes for all citizens.

03 — Pharma Services

Building on our current strength as the home to most of the leading Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs) in the country, Telangana sets an ambitious target. We envision transforming the current USD 2 billion revenue contribution from pharma services into a robust USD 10 billion industry. This expansion reflects our commitment to not only maintain our leadership in the services sector but also to grow exponentially, diversify, and contribute significantly to the economic landscape of the State. Strengthening this momentum, Hyderabad is now home to the Innovative Pharmaceutical Services Organization (IPSO), a pioneering initiative by leading CRDMOs. IPSO seeks to enhance industry capabilities, collaborate with the government on regulations, nurture talent, and fortify the supply chain, driving innovation and global growth while contributing significantly to the State’s economy.

04 — Diagnostics & Medical Electronics

The Policy also emphasizes the creation of a strong hub for Diagnostics, Precision Engineering, and Medical Electronics Manufacturing and R&D. By nurturing a collaborative ecosystem that unites industry leaders, research institutions, and technology innovators, Telangana aims to position itself as a major centre for medical technologies and diagnostics.

05 — Global Value Centres and Global Innovation Centres

Telangana has the distinct honour of hosting the Global Value Centres of many of the world’s most valuable firms across Life Sciences, Healthcare, and Technology sectors. This unique advantage empowers us to build cutting-edge capabilities that can be leveraged by our industry partners. Our initiative focuses on both “India for India” and “India for the World,” reflecting a dual commitment to national and global excellence.

06 — Precision Medicine and Personalized Therapies

The Government of Telangana is advancing Precision Medicine by establishing clinical registries for critical diseases and creating comprehensive digital health records for every citizen. In full compliance with privacy laws, this data will support personalized treatment plans, enhance healthcare delivery, and drive scientific R&D.

Cutting across these pivotal verticals, the government is poised to channel its efforts through a strategic array of instruments designed to foster unparalleled growth within the life sciences ecosystem. Our commitment to excellence extends to every facet of this transformative journey, where we recognize the critical role that various instruments play in sculpting a thriving and innovative environment.

6Strategic Levers

As we set the stage for unprecedented progress, the government will strategically leverage the following instruments: Infrastructure, Talent, Regulatory Ease, Funding and Ancillary Ecosystem.

6.1Creating State-of-the-Art Infrastructure

Investing in state-of-the-art infrastructure is central to our commitment to building a robust foundation for research, development, and manufacturing, ensuring a seamless journey from innovation to production. The State has already set unmatched benchmarks through the establishment of highly successful clusters such as Genome Valley and the Medical Devices Park. To meet the growing demand from industry, the Government is committed to expanding Genome Valley and the Medical Devices Park. This initiative is aimed at reinforcing Telangana’s position as a leading destination for the medical devices and diagnostics sector. In line with this vision, the Government is also focused on establishing new clusters and expanding existing ones to further accelerate the growth of the life sciences sector.

6.1.1 Green Pharma City

A flagship initiative of the Government of Telangana, is a world-class, sustainable industrial cluster designed to transform pharmaceutical manufacturing and R&D. Strategically located just about 25 km from the Hyderabad International Airport as part of the Bharat Future City project, it offers seamless connectivity to major industrial zones, including the emerging AI Hub. The project integrates advanced infrastructure with green practices such as zero liquid discharge, centralized waste management, and energy-efficient systems. It has been meticulously designed around a “Work, Live, Learn, and Play” philosophy, ensuring a world-class ecosystem. Additionally, the presence of Young India Skills University (YISU) in the vicinity makes it an ideal location and guarantees a steady pipeline of skilled talent to meet the evolving workforce demands within the cluster. Green Pharma City reinforces Telangana’s position as a global life sciences hub, serving as a benchmark for responsible, future-ready pharmaceutical development through its commitment to ecological sustainability and strict adherence to green category regulations.

6.1.2 Flagship Pharma Villages Initiative

Telangana is unwaveringly committed to establishing cutting-edge Pharma Villages, envisioned with state-of-the-art common utility infrastructure to bolster the global competitiveness of industries. These villages will serve as vibrant hubs, fostering an ecosystem conducive to research, development, and manufacturing. The government intends to develop 10 Pharma Villages, each spanning between 1,000 and 3,000 acres, along 14 radial roads on the Outer Ring Road (ORR), which connect to 12 national highways, ensuring equitable growth and development across the state. The project will be implemented in phases to cater to the emerging demands of the industry, and the government has announced three parks to begin with.

• —Designed to accommodate state-of-the-art infrastructure for pharmaceutical manufacturing, research, and development
• —Strategically located within the vicinity of major transportation routes and urban centres
• —Training & Skill Development institutes / skill universities
• —Advanced Utility Infrastructure with focus on Net Zero
• —Dormitories & amenities for employees
• —Healthcare facilities and wellness centres

6.1.3 Bio-Innovation and Bio-Manufacturing Cluster

Telangana, a leading state in India’s biotech sector, is aligning with the government of India’s BioE3 policy to further strengthen its capabilities in precision fermentation and cell and gene therapy (CGT). Building on its strong foundation in vaccine development and biosimilars, Telangana aims to become a global hub for these emerging technologies, driving economic growth and improving public health.

By investing in research, infrastructure, and a skilled workforce, the state is well-positioned to capitalize on the immense potential of biotechnology. The Government proposes to place maximum emphasis on biomanufacturing in the expansion of Genome Valley, spread over 300 acres. Industries focused on bio-catalysis and precision fermentation technologies will be actively encouraged. The park will also include a fully integrated Bio-manufacturing Cluster to serve as a launchpad for companies and assist them in establishing proof-of-concept.

Furthermore, the government is keen on developing and supporting the establishment of multi-tenanted lab spaces and flatted factories across all industrial areas, including Genome Valley, Medical Devices Park, and Pharma Villages, etc. These spaces, equipped with advanced infrastructure and shared resources, will foster collaboration and innovation among diverse entities. The role of these multi-tenanted lab spaces is pivotal in accelerating discoveries, reducing costs, and enhancing overall efficiency within the sector.

To further augment the scientific landscape, Telangana envisions establishing a robust scientific support infrastructure. This comprehensive initiative includes the development of common testing labs, scale-up infrastructure, and other critical facilities. These additions will not only streamline processes but also lower barriers to entry for smaller players in the industry, fostering a more inclusive and innovative life sciences ecosystem.

6.1.4 Driving Sustainable Growth: Telangana’s Commitment to Environmentally Responsible Industrial Development

Sustainability will remain central to all our efforts to promote infrastructure and industrial clusters. Every effort will be made to minimize emissions and waste through advanced technologies, responsible industrial practices, and a strong regulatory framework. Importantly, stringent rules and proactive measures will be adopted to minimize and mitigate pollution-related aspects.

All industrial parks will feature centralized waste management infrastructure, including Zero Liquid Discharge (ZLD) systems and Common Effluent Treatment Plants (CETPs), deploying the most advanced technologies, to ensure that no untreated waste harms the environment.

Telangana’s approach is clear: growth must be sustainable, inclusive, and aligned with global environmental standards. Through this balance, the state aims to create a model ecosystem where innovation in life sciences thrives hand in hand with environmental stewardship.

6.2Cultivating a Dynamic Talent Ecosystem for Unprecedented Quality and Scale

In our commitment to fortify the life sciences sector, we recognize that a skilled and dynamic workforce is the bedrock of success. Therefore, our strategy is dedicated to fostering a robust talent ecosystem that not only meets but also anticipates evolving industry needs. Our programs will focus on building capabilities and scaling across the talent pyramid through strategic partnerships.

Additionally, the government is establishing the Telangana School of Life Sciences under the Telangana Private Universities Act, envisioned as a world-class institution dedicated to nurturing advanced talent and serving as a catalyst for innovation and discovery research in the life sciences sector. The Government of Telangana has already established TASK — Telangana Academy of Skill and Knowledge to bring synergy among institutions of government, Industry & Academia to offer quality human resources and services to the industry.

Recently, the government, under the leadership of Hon’ble Chief Minister and Industries Minister launched YISU — Young India Skills University to equip India’s youth with the skills and knowledge required for the evolving job market by providing high-quality, industry-integrated education.

01 — Scientific & Advanced Skills

To ensure a workforce equipped with the latest skills and knowledge, we have launched targeted training programs. These initiatives, designed in collaboration with industry and educational institutions, closely align with the current and future needs of the life sciences domain. By offering specialized training modules, our aim is to bridge the skills gap, empowering individuals to meaningfully contribute to the sector’s growth.

02 — Skill-based Education

We plan to enhance academic curriculum by integrating real-world industry insights and facilitating internships that provide students with practical experiences, ultimately improving productivity and aiding companies in scaling. By aligning academic learning with industry requirements, we intend to produce graduates well-versed in theory and ready to make immediate, impactful contributions to the workforce. The initial programs are focused on core strengths in Telangana, such as Medicinal Chemistry, Analytical Chemistry, Biologics, Digital capabilities like AI/ML, Gen AI, Bioinformatics, Health Outcomes and Economic Research (HOER), program management in life sciences, etc.

03 — Continuous Learning Initiatives

In a rapidly evolving sector like life sciences, the pursuit of knowledge must be continuous. To support this, we are establishing initiatives focused on lifelong learning. These programs will provide professionals with opportunities to upskill and stay up to date of the latest advancements in their respective fields. By promoting a culture of continuous learning, our goal is to create a workforce that thrives on innovation and remains adaptable to the ever-changing landscape of the life sciences sector.

04 — World-Class Life Sciences University

As mentioned earlier, the Government of Telangana is establishing the Telangana School of Life Sciences as a globally benchmarked institution with a focused mandate on life sciences education and research. The university will serve as a catalyst for innovation, talent development, and discovery, offering a portfolio of programs including Ph.D., Master’s, Undergraduate, and Professional Certification programs.

In essence, our focus on strengthening the Talent Ecosystem goes beyond meeting industry demands; it is about shaping a workforce that propels the sector’s growth, fosters innovation, and positions Telangana at the forefront of life sciences.

6.3Ancillary Ecosystem Development

We recognize the pivotal role of an integrated and flourishing ancillary ecosystem. This development extends beyond the core activities of research, development, and manufacturing; it encompasses the creation of a robust network of services, suppliers, and partners that collectively contribute to the efficiency of the life sciences community.

An integral aspect of the ancillary ecosystem is the facilitation of a dynamic network of suppliers catering to the unique needs of life sciences entities. Whether it be sourcing raw materials, equipment, or specialized technology, our focus is on creating a symbiotic relationship between suppliers and life sciences companies. This collaboration not only ensures a streamlined supply chain but also promotes innovation and competitiveness within the sector.

This holistic approach ensures that Telangana’s life sciences community thrives, evolves, and remains at the forefront of global innovation and excellence. Government will set up a structured and dedicated forum, including an online platform, for the emerging suppliers and service providers to connect with the companies for mutual benefit. Government will also place special emphasis on promoting ancillary industry within the life sciences clusters including flagship Pharma Villages initiative, Genome Valley and other industrial clusters.

6.4Regulatory Streamlining & Ease-of-Doing Business

Telangana’s commitment to regulatory streamlining at the state level is rooted in the recognition that a conducive business environment is pivotal for the growth of the life sciences sector. The policy aims to identify redundancies, minimize procedural complexities, and expedite approval processes without compromising safety standards.

The Government of Telangana will form a Consultation Committee under the chairmanship of the Special Chief Secretary, Industries & Commerce Department, Government of Telangana. Members of the committee will include representation from the Telangana State Pollution Control Board, Telangana Drugs Control Administration, and industry stakeholders to simplify and enhance the approval process. By doing so, we intend to create an environment that encourages investment, innovation, and overall industry advancement within the state’s jurisdiction.

Further, understanding the broader impact of central regulations on the life sciences industry, Telangana aspires to play a leading role in advocating for streamlined processes at the central level. By acting as a vocal advocate, Telangana endeavors to contribute to a regulatory landscape that is not only efficient but also aligned with global best practices.

6.5Funding Ecosystem

In a strategic move to catalyze transformative advancements within the life sciences sector, Telangana is committed to establishing a robust funding ecosystem, underpinned by a dedicated Innovation Fund of USD 12 million (INR 100 Crore) to begin with, and subsequently scaled up to USD 120 million (INR 1000 Crore) over time. This initiative, proposed in a public-private partnership model, aims to not only fuel groundbreaking research but also provide vital support to startups. In its steadfast commitment to fostering innovation and propelling the life sciences sector to new heights, Telangana’s Life Sciences Policy extends a warm invitation to Venture Capital (VC) and Private Equity (PE) players, urging them to establish a strong presence within the state.

To sweeten the deal, Telangana is committed to co-investing with VCs through the Innovation Fund. A combination of a world-class ecosystem, enabling infrastructure, unmatched talent pool, regulatory ease, and government co-investment will set Telangana apart from the rest of the country and the region.

7Incentives

Building on the foundation of the State’s industrial policy, this policy introduces targeted financial incentives to stimulate investment, encourage entrepreneurship, and drive economic growth within the life sciences sector.

Investments made post-policy launch will be eligible for incentives. While the existing T-IDEA Policy and MSME Policy continues to support new and expanding establishments, this Life Sciences Policy additionally emphasizes emerging segments such as Advanced Manufacturing, Pharma Services, Global Value Centres, and the Medical Devices industry.

Industry classifications are provided in Annexure I, and the common incentive structure is detailed below. The MSME Policy of the state of Telangana is also available to be utilised by potential investors. Additional incentives will be provided for new units being set up beyond the Regional Ring Road (RRR) area. The quantum of incentives will be decided by Telangana Life Sciences Foundation (TLSF) on a case-to-case basis.

The Government of Telangana will actively support all units in securing Central Government subsidies.

7.1General Incentives

A new life sciences unit undertaking investment in the manufacture or provision of life sciences products or services, or an existing unit undergoing expansion or diversification, will qualify for incentives under this policy. If an existing unit makes an investment at a new location, without relocating its current plant or assets within the State it will be considered a new eligible unit. The common incentives applicable to life sciences industry units are in accordance with the state government’s Industrial Policy.

7.2Local Employment Policy

Industries can benefit from the local employment policy by gaining access to a readily available, skilled workforce, reducing recruitment costs and improving operational efficiency.

Hiring locally creates a mutually beneficial ecosystem where companies meet talent needs while locals gain stable employment and skill development opportunities.

7.3Additional Incentives for Focus Industries

This section describes incentives provided in addition to the general incentives applicable to focus industries.

01 — R&D Units

Under this new policy, R&D activities/units within the pharmaceutical sector will be treated as equivalent to any other industrial unit under Clause 6 of the T-IDEA scheme. Additionally, as per the directive from the Department of Industries dated 20-05-2023, R&D has been recognized as a crucial element for industrial expansion and value creation. Consequently, it has been considered eligible for an incentive structure equivalent to that of industrial manufacturing units. This policy establishes pharmaceutical R&D activities as industrial units, making them eligible for incentives under the T-IDEA scheme on par with other qualifying industrial activities.

02 — Advanced Manufacturing

• —Power Subsidy: Fixed power cost reimbursement of INR 2.00 per unit for a period of five (5) years from the date of commencement of commercial production.
• —Investment Subsidy – Standard: 25% of capital investment in plant and machinery (excluding land and building), subject to a maximum of INR 20 crore for large units; 50% for MSMEs up to INR 10 crore.
• —For industries beyond the proposed RRR: 30% of capital investment in plant and machinery (excluding land and building), subject to a maximum of INR 30 crore for large units; 50% for MSMEs up to INR 20 crore.
• —Eligible units must qualify under the activity focus areas outlined in Subsection 5.4. The list of eligible activities may be revised from time to time.

03 — Pharma Villages

• —The government will offer land at a highly subsidized rate for industries.
• —Five anchor investors (with an investment of more than INR 500 crore within three years) will be identified for each Pharma Village.
• —The government, through the Industrial Infrastructure Corporation, will develop all necessary infrastructure, including roads, power, and water facilities.
• —The government will place special emphasis on developing world-class environmental infrastructure, including a CETP with ZLD, etc. This will be developed through the PPP model in partnership with a globally reputed agency. The government will ensure that the cost of treatment remains competitive for industries, through subsidies if required.
• —Investment Subsidy: 15% capital investment subsidy on fixed capital investment in plant and machinery (excluding land and building costs), subject to a maximum of INR 20 crore for large units, and 25% for MSMEs, up to INR 5 crore.
• —The government will adopt a co-generation model for the production of steam and electricity, to ensure a reduced carbon footprint and improved global compliance.
• —The government will facilitate the development of worker dormitories in the Pharma Villages.

04 — Global Value Centres (GVCs) & Global Innovation Centres (GICs)

GVCs and GICs applying for incentives under this category will not be eligible to apply for incentives under the IT/ ITeS policy of the Government of Telangana. Incentives under this category will not be applicable for Mega Investors.

Companies with offices under the HMDA area, can avail the below incentives once in the policy period:

• —Skilled Workforce Development: Government will reimburse 20% of the total cost incurred on upskilling/reskilling initiatives undertaken by the company for up to 100 employees or 10% of their workforce subject to a cap of INR 1 crore.
• —Power Subsidy: Additional fixed power cost reimbursement @ INR 1.00 per unit for 3 years subject to a cap of INR 1 crore.
• —Quality Certifications: Reimbursement for certification costs of up to 3 quality certifications, capped at INR 5 lakh per company. The list of applicable quality certifications is annexed – Annexure II.

Companies with offices under all other areas, can avail the below incentives once in the policy period:

• —Skilled Workforce Development: Government will reimburse 40% of the total cost incurred on upskilling/reskilling initiatives undertaken by the company for up to 200 employees or 20% of their workforce subject to an upper cap of INR 2 crore.
• —Power Subsidy: Additional fixed power cost reimbursement @ INR 2.00 per unit for 3 years subject to an upper cap of INR 2 crore.
• —Quality Certifications: Reimbursement for certification costs of up to 5 quality certifications, capped at INR 7.5 lakh per company. The list of applicable quality certifications is annexed – Annexure II.

Common Incentives for all GVCs & GICs irrespective of location:

• —Research Collaborations / Acquisitions: Government of Telangana will reimburse 50% of the research grant amount provided for projects jointly conducted with universities based in Telangana. This reimbursement will be subject to a maximum limit of INR 1 crore per Project.
• —For GVCs & GICs: Investing in or acquiring startups, MSMEs, or companies with registered headquarters in Telangana and continuous operations in Telangana for the last five years, the government will reimburse 20% of the transaction value, capped at INR 1 crore per transaction subject to a financial audit check by authorities approved by the Government of Telangana.
• —Collaborative Ecosystem – Life Sciences Global Capability Centres (GCCs) Consortium: The government has created a platform for life sciences GCCs to collaborate, share best practices, and work together on large-scale projects or common minimum programs. This platform shall be an ongoing exercise.

05 — Medical Electronics and Diagnostics

• —Promoting Local Procurement: Companies sourcing raw materials, surgical equipment, and related inputs from local vendors will be accorded preferential procurement benefits. Local manufacturers will receive 5–10% weightage in tender evaluations to encourage local sourcing.
• —Common Facilities and Expansion: The government, through the Industrial Infrastructure Corporation, will expand the Medical Devices Park and develop essential infrastructure — roads, reliable power supply and water facilities. Common facilities will be established based on tenant requirements, and plug-and-play infrastructure will be promoted similar to Genome Valley.
• —Promotional Support: The Government of Telangana, through the Telangana Life Sciences Foundation, will actively promote the Medical Devices and Diagnostics ecosystem at national and international forums.
• —Power Reimbursement: A fixed power subsidy of INR 1.00 per unit will be extended to the medical diagnostic companies for an additional five (5) years from the commencement of commercial production. All other incentives pertaining to medical electronics will benefit from the Electronics Policy of the State Government of Telangana.

06 — Research Talent and Collaboration Incentives

To further strengthen Telangana’s position as a global hub for life sciences research and innovation, the Government will institute a Scholarship for Joint Research Excellence. This initiative will incentivize collaborative research programs between institutions in Telangana and researchers pursuing post-doctoral, India-specific life sciences research in the top 100 global universities and institutes. Guidelines governing eligibility, selection criteria, and disbursement mechanisms under this scheme will be issued separately.

In addition, the Government will collaborate with national and international initiatives aimed at fostering high-impact scientific research and talent mobility. In particular, the Government will work with programs such as the India Reimagined Fellowship — a major national initiative launched by Blockchain for Impact (BFI) to attract exceptional scientific and professional talent to India. The fellowship provides grants of up to USD 300,000 (approximately INR 2.5 crore) over three years to researchers, entrepreneurs, clinicians, and innovators of Indian or international origin who are willing to relocate to India and undertake transformative R&D projects.

Through such partnerships and dedicated talent programs, Telangana seeks to build a strong pipeline of globally connected researchers and to reinforce its leadership in cutting-edge life sciences research, translational innovation, and collaborative scientific advancement.

8Ease of Doing Business

01Effective Single Window Policy

The government has established an efficient system to facilitate industrial development, moving beyond the traditional approach. The life sciences sector will also benefit from this streamlined approval mechanism, known as the Telangana Industrial Project Approval and Self-Certification System (TG-iPASS), which is being reinforced through legislation. Similar to the Right to Information, a Right to Single Window Clearance will be extended to all applicants.

To apply for state incentives, visit www.telangana.gov.in and complete the common online application.

02Time Bound Approvals

The TG-iPASS Act allows entrepreneurs to obtain various clearances required for setting up businesses in a streamlined manner, with specific time limits for approvals, ranging from 1 to 30 days. Additionally, entrepreneurs are granted the Right to Clearances under TG-iPASS, enabling them to understand the reasons for any delays in obtaining approvals within the specified time limits. If approvals are not granted within four weeks of receiving a complete application, the application will be deemed approved by default.

03Labour Concessions

Recognizing the necessity for continuous operations in the knowledge-intensive life sciences sector, the government has decided to ease labor regulations by granting general permission for 24x7 operations in three shifts for life sciences units located in designated Industrial Parks. This flexibility in working hours and schedules is subject to the implementation of approved safety measures, with a particular emphasis on the well-being and security of female employees. This initiative reflects the government’s commitment to fostering an environment that supports uninterrupted productivity, while prioritizing the health and safety of the workforce in Telangana’s Life Sciences industry.

04Industrial Area Local Authority (IALA)

To enhance the maintenance of civic services within Industrial Parks, the government has granted Local Authority status to TGIIC under Section 147 of the TSPR Act, 1994. The government has also issued orders designating IALAs as Industrial Townships, allowing them to function as independent Local Authorities, contingent upon TGIIC remitting 35% to 50% of the collected property tax/revenue to the relevant Local bodies.

To foster local self-governance in industrial areas, TGIIC has introduced the concept of Industrial Area Service Societies, engaging the taxpayer community in the management and maintenance of these areas.

Furthermore, to streamline business operations, TGIIC-IALAs have introduced online services for obtaining building permissions through Development Permission Management System, and for the payment of property tax dues, as well as fees for road cutting and water connections, thereby promoting Ease of Doing Business.

9Governance Mechanism

Telangana Life Sciences Foundation

The Telangana Life Sciences Foundation (TLSF) is a Section 8 registered organization, incorporated by the Government of Telangana. It was established with the objective of promoting investments in life sciences, pharmaceuticals, medical devices, biotechnology, and health-tech sectors; building a robust ecosystem for industry, startups, and MSMEs; and conceptualizing initiatives such as the establishment of global Centres of Excellence (CoEs), skilling programs, networking events, and more. It functions as a liaison between government bodies, industry stakeholders, academia, and research institutions, facilitating dialogue, collaboration, and strategic partnerships to address key challenges and leverage opportunities for growth and innovation.

The Foundation functions under the direction of a Board of Directors, chaired by the Hon’ble Minister for Industries and Commerce, with the Special Chief Secretary (Industries and Commerce) serving as Vice Chair. It will serve as the nodal agency for implementation of the new Life Sciences Policy, in coordination with relevant agencies such as the Telangana Industrial Infrastructure Corporation (TGIIC), the Commissioner of Industries, and others.

Telangana State Life Sciences Advisory Committee

The government has also constituted a Life Sciences Advisory Committee to serve as a structured interface between the government, industry, and academia. The committee has advised on a wide range of aspects related to the development of the Life Sciences and MedTech sectors in Telangana.

The Advisory Committee will continue to function as a consultative body, entrusted with providing strategic guidance and expert insights to shape policies, initiatives, and decisions related to the life sciences sector in the State. Comprising esteemed experts and industry leaders, the committee convenes regularly to offer recommendations on critical matters such as research, growth, investment, and regulatory frameworks.

10Conclusion

The Telangana Life Sciences Policy 2025–2030 represents a bold and visionary roadmap to solidify the state’s position as a global leader in the life sciences sector. By leveraging its established strengths in pharmaceutical manufacturing, vaccine production, and R&D, while strategically diversifying into emerging fields such as biologics, precision medicine, and biomanufacturing, Telangana is poised to redefine healthcare and life sciences innovation.

The policy’s multifaceted approach, encompassing state-of-the-art infrastructure, a dynamic talent ecosystem, regulatory streamlining, and incentives creates a conducive environment for industry growth, entrepreneurship, and global collaboration. With a focus on inclusivity, accessibility to innovative therapies, and socio-economic progress, this policy positions Telangana to not only drive economic prosperity but also contribute significantly to global health and well-being by 2030.

11Annexure I — Industry Classification

Govt of India MSME Definition

S.O. 1364(E).—In exercise of the powers conferred by sub-section (1) read with sub-section (9) of section 7 and sub-section (2) read with subsection (3) of section 8 of the ‘Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006)’, the Central Government after obtaining the recommendations of the Advisory Committee in this behalf hereby makes the following amendments in the notification of Government of India, Ministry of Micro, Small and Medium Enterprises number S.O. 2119 (E), dated the 26th June, 2020, published in the Gazette of India, Extraordinary, Part-II, Section 3, sub-section (ii), dated the 26th June, 2020, namely:

• —A micro enterprise, where the investment in Plant and Machinery or Equipment does not exceed INR 2.5 crore and turnover does not exceed INR 10 crore.
• —A small enterprise, where the investment in Plant and Machinery or Equipment does not exceed INR 25 crore and turnover does not exceed INR 100 crore.
• —A medium enterprise, where the investment in Plant and Machinery or Equipment does not exceed INR 125 crore and turnover does not exceed INR 500 crore.

Annexure II — List of Quality Certifications

• —CMM Level 4 Upwards
• —ISO: International Organization for Standardization
• —HACCP: Hazard Analysis and Critical Control Points
• —BIS: Bureau of Indian Standards
• —WHO-GMP: World Health Organization – Good Manufacturing Practices
• —ZED: Zero Defect Zero Effect
• —TS: Technical Specifications
• —COPC: Customer Operations Performance Centre
• —eSCM: eSourcing Capability Model
• —Hallmark: Hallmark certification, as approved by the Quality Council of India
• —Any other certificates as recognized by the government

Annexure III — Abbreviations

Contact

Shakthi M Nagappan
Director (Life Sciences & Pharma)
Chief Executive Officer, Telangana Life Sciences Foundation
3rd Floor, HGCL Office Building, Nanakramguda, Hyderabad – 500 032
M: +91 40 23452077 · dir_lifesciences@telangana.gov.in